Intermediate Risk Clinical Trials in Aarhus
2 recruitingAarhus, Denmark
Showing 1–2 of 2 trials
Recruiting
Phase 3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals454 enrolled103 locationsNCT06510374
Recruiting
Not Applicable
Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions
Locally Advanced Prostate CancerProstate Cancer Patients Undergoing External Radiation and Seed ImplantationHigh Risk Localised Prostate Carcinoma+1 more
Rigshospitalet, Denmark1,016 enrolled3 locationsNCT07343349